Sentry Investment Management LLC Increases Stock Position in AxoGen, Inc. (NASDAQ:AXGN)

by · The Cerbat Gem

Sentry Investment Management LLC boosted its position in AxoGen, Inc. (NASDAQ:AXGN – Free Report) by 9.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 17,368 shares of the medical equipment provider’s stock after purchasing an additional 1,483 shares during the period. Sentry Investment Management LLC’s holdings in AxoGen were worth $243,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. nVerses Capital LLC bought a new stake in shares of AxoGen during the third quarter valued at about $56,000. Koss Olinger Consulting LLC bought a new position in shares of AxoGen in the second quarter worth approximately $75,000. Lazard Asset Management LLC increased its position in shares of AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock worth $93,000 after purchasing an additional 2,671 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of AxoGen during the third quarter worth approximately $227,000. Finally, Acadian Asset Management LLC purchased a new position in shares of AxoGen during the second quarter worth approximately $125,000. Institutional investors own 80.29% of the company’s stock.

AxoGen Stock Performance

NASDAQ AXGN opened at $14.20 on Tuesday. The firm has a market cap of $622.39 million, a price-to-earnings ratio of -37.37 and a beta of 1.13. The business has a 50-day moving average price of $13.71 and a 200-day moving average price of $9.95. AxoGen, Inc. has a twelve month low of $3.92 and a twelve month high of $15.23. The company has a quick ratio of 2.32, a current ratio of 3.51 and a debt-to-equity ratio of 0.70.

AxoGen (NASDAQ:AXGN – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. The firm had revenue of $47.91 million during the quarter, compared to the consensus estimate of $43.27 million. As a group, equities research analysts predict that AxoGen, Inc. will post -0.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. JMP Securities raised their target price on shares of AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a report on Friday, August 9th. StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $15.00.

Check Out Our Latest Stock Analysis on AXGN

AxoGen Company Profile

(Free Report)

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

See Also

Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN – Free Report).